Recombinant porcine factor VIII (rpFVIII; Obizur, Susoctocog-alfa) was commissioned by
NHS England in June 2018 as a first line treatment option for actively bleeding patients with …

Abstract Background Acquired haemophilia A (AHA) is a rare acquired bleeding disorder
that can present with life‐threatening bleeding. Aims To describe recent Australian use of …

Acquired haemophilia A (AHA) is a rare, serious bleeding disorder most often encountered
in elderly patients. The mainstay of haemostatic management is with bypassing agents …

Introduction A recombinant porcine factor VIII B‐domain‐deleted product (rp FVIII; OBIZUR,
Baxalta Incorporated, Deerfield, IL 60015, USA) was recently approved for treatment of …

Abstract Introduction Acquired haemophilia A (AHA) is a rare bleeding disorder caused by
development of auto‐antibodies to endogenous coagulation factor VIII (FVIII). Recombinant …

Introduction Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the
treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Aim To provide …

The author discusses the progress in the development of recombinant porcine factor VIII
(FVII) for treatment of patients with haemophilia, with particular consideration on its …

Background: Recombinant porcine factor VIII (rpFVIII; susoctocog alfa) is indicated for the
treatment of bleeding events (BEs) in adults with acquired hemophilia A (AHA). Objectives …

Acquired hemophilia A (AHA) is a rare bleeding disorder in which acquired autoantibodies
to endogenous factor VIII (FVIII) decrease FVIII activity and lead to a bleeding phenotype. A …

Acquired hemophilia A (AHA) is a rare disorder in which an acquired autoantibody inhibits
the activity of coagulation factor VIII. It affects an estimated 1 per million population annually …